Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Celgene’s Bet On Abraxis Helps Spur Host Of Nanomedicine Start-Ups

Executive Summary

Second-generation therapeutics are moving into the clinic following Celgene’s successful gamble on Abraxane. New nanobiotechs proliferate, but an industry burned by other promising technology revolutions remains somewhat wary of investing in early-stage firms.

You may also be interested in...



Deals Of The Week: Tire-Kicking Season Continues Full-Swing

As Roche’s reported interest in buying rare-disease specialist Alexion faded, new suitors popped up for oncology specialist Onyx. Plus news on deals between Spectrum and Talon, Pfizer and Sequella, Medtronic and Amgen, and a new direction for Rexahn.

Spectrum Bets On Marqibo In NHL With Low-Priced Talon Acquisition

Spectrum gains an approved drug with the deal and aims for label expansion. Talon’s high-profile investors are counting on an increase in Spectrum share price and post-acquisition milestones to break even.

Celgene Goes Big And Early: Aims For Two New Blockbusters And A Robust, Transformative Pipeline

The biotech has a three-pronged strategy to double revenues by 2017: continue to expand core multiple myeloma product Revlimid, bring new blockbusters online, and develop its early stage pipeline through deals.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

ID007083

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel